Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pharvaris N.V.PHVS · Entity 4374 | President | October 11, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pharvaris N.V.
Report date October 11, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 110,035 |
Ending reported balance
After 2026-10-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-11 · Tax withholding · Disposed 109 · Balance 110,152 F1: Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units. Row 2 · 2026-10-12 · Tax withholding · Disposed 117 · Balance 110,035 F1: Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2026 Filed Oct 13, 2026 20:10 UTC | Pharvaris N.V. PHVS · Entity 4374 | Tax withholdingCommon Stock | 117 | $31.10 | $3,638.70 |
DisclosureSEC source: 0001193125-26-420425 · ownership.xml · nonDerivative · entry 2 Lu Peng · CIK 0001972159 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,035 F1 · shares: Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| October 11, 2026 Filed Oct 13, 2026 20:10 UTC | Pharvaris N.V. PHVS · Entity 4374 | Tax withholdingCommon Stock | 109 | $31.10 | $3,389.90 |
DisclosureSEC source: 0001193125-26-420425 · ownership.xml · nonDerivative · entry 1 Lu Peng · CIK 0001972159 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,152 F1 · shares: Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:03 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,308 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001193125-26-401007 · ownership.xml · derivative · entry 2 Lu Peng · CIK 0001972159 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,308 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:03 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 45,308 | $2.59 | $117,347.72 |
DisclosureSEC source: 0001193125-26-401007 · ownership.xml · nonDerivative · entry 1 Lu Peng · CIK 0001972159 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:20 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 86,692 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001193125-26-396695 · ownership.xml · derivative · entry 4 Lu Peng · CIK 0001972159 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,308 Underlying: Common Stock · 86,692 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:20 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,308 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001193125-26-396695 · ownership.xml · derivative · entry 3 Lu Peng · CIK 0001972159 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,308 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:20 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 100,000 | $35.00 | $3,500,000.00 |
DisclosureSEC source: 0001193125-26-396695 · ownership.xml · nonDerivative · entry 2 Lu Peng · CIK 0001972159 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,953 Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:20 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 100,000 | $2.59 | $259,000.00 |
DisclosureSEC source: 0001193125-26-396695 · ownership.xml · nonDerivative · entry 1 Lu Peng · CIK 0001972159 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2026 Filed Sep 15, 2026 18:30 UTC | Pharvaris N.V. PHVS · Entity 4374 | Tax withholdingCommon Stock | 117 | $38.02 | $4,448.34 |
DisclosureSEC source: 0001193125-26-391740 · ownership.xml · nonDerivative · entry 4 Lu Peng · CIK 0001972159 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,953 F3 · shares: Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 18:30 UTC | Pharvaris N.V. PHVS · Entity 4374 | Tax withholdingCommon Stock | 109 | $37.51 | $4,088.59 |
DisclosureSEC source: 0001193125-26-391740 · ownership.xml · nonDerivative · entry 3 Lu Peng · CIK 0001972159 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,070 F3 · shares: Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 18:30 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 15,000 | $40.13 | $601,947.00 |
DisclosureSEC source: 0001193125-26-391740 · ownership.xml · nonDerivative · entry 2 Lu Peng · CIK 0001972159 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,179 F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F2 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $40.00 to $40.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 18:30 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 15,000 | $2.59 | $38,850.00 |
DisclosureSEC source: 0001193125-26-391740 · ownership.xml · nonDerivative · entry 1 Lu Peng · CIK 0001972159 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 15:19 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 15,000 | $40.68 | $610,134.00 |
DisclosureSEC source: 0001193125-26-386096 · ownership.xml · nonDerivative · entry 2 Lu Peng · CIK 0001972159 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,179 F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F2 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $40.50 to $40.80. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 15:19 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 15,000 | $2.59 | $38,850.00 |
DisclosureSEC source: 0001193125-26-386096 · ownership.xml · nonDerivative · entry 1 Lu Peng · CIK 0001972159 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 20:35 UTC | Pharvaris N.V. PHVS · Entity 4374 | Tax withholdingCommon Stock | 117 | $34.42 | $4,027.14 |
DisclosureSEC source: 0001193125-26-349371 · ownership.xml · nonDerivative · entry 2 Lu Peng · CIK 0001972159 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,179 F1 · shares: Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| August 11, 2026 Filed Aug 13, 2026 20:35 UTC | Pharvaris N.V. PHVS · Entity 4374 | Tax withholdingCommon Stock | 109 | $34.84 | $3,797.56 |
DisclosureSEC source: 0001193125-26-349371 · ownership.xml · nonDerivative · entry 1 Lu Peng · CIK 0001972159 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,296 F1 · shares: Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| July 12, 2026 Filed Jul 14, 2026 19:46 UTC | Pharvaris N.V. PHVS · Entity 4374 | Tax withholdingCommon Stock | 117 | $35.07 | $4,103.19 |
DisclosureSEC source: 0001193125-26-303097 · ownership.xml · nonDerivative · entry 2 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,405 F1 · shares: Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| July 11, 2026 Filed Jul 14, 2026 19:46 UTC | Pharvaris N.V. PHVS · Entity 4374 | Tax withholdingCommon Stock | 109 | $35.07 | $3,822.63 |
DisclosureSEC source: 0001193125-26-303097 · ownership.xml · nonDerivative · entry 1 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,522 F1 · shares: Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| June 26, 2026 Filed Jun 29, 2026 22:18 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,700 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001193125-26-288838 · ownership.xml · derivative · entry 7 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,308 Underlying: Common Stock · 14,700 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F5 · derivative.exercise_date: 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter. Read SEC document |
| June 26, 2026 Filed Jun 29, 2026 22:18 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 14,700 | $34.00 | $499,847.04 |
DisclosureSEC source: 0001193125-26-288838 · ownership.xml · nonDerivative · entry 5 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,631 F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F4 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $34.00 to 34.02. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 26, 2026 Filed Jun 29, 2026 22:18 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 14,700 | $2.59 | $38,073.00 |
DisclosureSEC source: 0001193125-26-288838 · ownership.xml · nonDerivative · entry 4 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 22:18 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001193125-26-288838 · ownership.xml · derivative · entry 6 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,008 Underlying: Common Stock · 15,000 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F5 · derivative.exercise_date: 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 22:18 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 3,400 | $35.09 | $119,310.42 |
DisclosureSEC source: 0001193125-26-288838 · ownership.xml · nonDerivative · entry 3 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,631 F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F3 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to 35.29. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 22:18 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 11,600 | $34.45 | $399,674.52 |
DisclosureSEC source: 0001193125-26-288838 · ownership.xml · nonDerivative · entry 2 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,031 F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F2 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $34.00 to $34.98. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 22:18 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 15,000 | $2.59 | $38,850.00 |
DisclosureSEC source: 0001193125-26-288838 · ownership.xml · nonDerivative · entry 1 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:07 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001193125-26-279753 · ownership.xml · derivative · entry 3 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,008 Underlying: Common Stock · 245,308 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F2 · derivative.exercise_date: 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:07 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 300 | $34.00 | $10,200.00 |
DisclosureSEC source: 0001193125-26-279753 · ownership.xml · nonDerivative · entry 2 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,631 F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:07 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 300 | $2.59 | $777.00 |
DisclosureSEC source: 0001193125-26-279753 · ownership.xml · nonDerivative · entry 1 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:50 UTC | Pharvaris N.V. PHVS · Entity 4374 | Tax withholdingCommon Stock | 117 | $32.20 | $3,767.40 |
DisclosureSEC source: 0001193125-26-272978 · ownership.xml · nonDerivative · entry 1 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,631 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units on June 12, 2026. The shares were withheld on June 12, 2026 at a fair market value of $32.20 per share. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:22 UTC | Pharvaris N.V. PHVS · Entity 4374 | Tax withholdingCommon Stock | 109 | $31.51 | $3,434.59 |
DisclosureSEC source: 0001193125-26-271314 · ownership.xml · nonDerivative · entry 1 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,748 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units on June 11, 2026. The shares were withheld on June 11, 2026 at a fair market value of $31.51 per share. Read SEC document |
| May 12, 2026 Filed May 13, 2026 22:48 UTC | Pharvaris N.V. PHVS · Entity 4374 | Tax withholdingCommon Stock | 117 | $29.95 | $3,504.15 |
DisclosureSEC source: 0001193125-26-222163 · ownership.xml · nonDerivative · entry 2 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,857 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units on May 12, 2026. The shares were withheld on May 12, 2026 at a fair market value of $29.95 per share. Read SEC document |
| May 11, 2026 Filed May 13, 2026 22:48 UTC | Pharvaris N.V. PHVS · Entity 4374 | Tax withholdingCommon Stock | 109 | $30.09 | $3,279.81 |
DisclosureSEC source: 0001193125-26-222163 · ownership.xml · nonDerivative · entry 1 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,974 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units on May 11, 2026. The shares were withheld on May 11, 2026 at a fair market value of $30.09 per share. Read SEC document |
| May 01, 2026 Filed May 5, 2026 19:51 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 143 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001193125-26-206273 · ownership.xml · derivative · entry 5 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,308 Underlying: Common Stock · 245,308 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F2 · derivative.exercise_date: 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter. Read SEC document |
| May 01, 2026 Filed May 5, 2026 19:51 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,023 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001193125-26-206273 · ownership.xml · derivative · entry 4 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,451 Underlying: Common Stock · 245,308 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F2 · derivative.exercise_date: 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter. Read SEC document |
| May 01, 2026 Filed May 5, 2026 19:51 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 143 | $31.00 | $4,433.00 |
DisclosureSEC source: 0001193125-26-206273 · ownership.xml · nonDerivative · entry 3 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,083 F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. Read SEC document |
| May 01, 2026 Filed May 5, 2026 19:51 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 14,023 | $30.16 | $422,985.57 |
DisclosureSEC source: 0001193125-26-206273 · ownership.xml · nonDerivative · entry 2 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,226 F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F3 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $30.00 to $30.99. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2026 Filed May 5, 2026 19:51 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 14,166 | $2.59 | $36,689.94 |
DisclosureSEC source: 0001193125-26-206273 · ownership.xml · nonDerivative · entry 1 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. Read SEC document |
| April 30, 2026 Filed May 1, 2026 23:09 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001193125-26-201906 · ownership.xml · derivative · entry 6 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 219,474 Underlying: Common Stock · 15,000 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter. F5 · balance_after: The number of derivative securities beneficially owned following the reported transaction has been updated to correct an error in the number of options remaining from this grant as previously reported. This correction does not reflect a new transaction. Read SEC document |
| April 30, 2026 Filed May 1, 2026 23:09 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 15,000 | $30.24 | $453,627.00 |
DisclosureSEC source: 0001193125-26-201906 · ownership.xml · nonDerivative · entry 4 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,083 F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F3 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.75 to $30.2418. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 30, 2026 Filed May 1, 2026 23:09 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 15,000 | $2.59 | $38,850.00 |
DisclosureSEC source: 0001193125-26-201906 · ownership.xml · nonDerivative · entry 3 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. Read SEC document |
| April 29, 2026 Filed May 1, 2026 23:09 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,733 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001193125-26-201906 · ownership.xml · derivative · entry 5 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 234,474 Underlying: Common Stock · 3,733 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter. F5 · balance_after: The number of derivative securities beneficially owned following the reported transaction has been updated to correct an error in the number of options remaining from this grant as previously reported. This correction does not reflect a new transaction. Read SEC document |
| April 29, 2026 Filed May 1, 2026 23:09 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 3,733 | $30.06 | $112,232.27 |
DisclosureSEC source: 0001193125-26-201906 · ownership.xml · nonDerivative · entry 2 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,350 F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F2 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.20. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 29, 2026 Filed May 1, 2026 23:09 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 3,733 | $2.59 | $9,668.47 |
DisclosureSEC source: 0001193125-26-201906 · ownership.xml · nonDerivative · entry 1 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 15:27 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001193125-26-175965 · ownership.xml · derivative · entry 6 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,207 Underlying: Common Stock · 100 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F4 · derivative.exercise_date: 25% of the option vested on February 3, 2020 with the remaining shares vesting in 1/48 monthly installments thereafter. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 15:27 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 100 | $30.03 | $3,003.00 |
DisclosureSEC source: 0001193125-26-175965 · ownership.xml · nonDerivative · entry 4 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,083 F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F3 · price: These shares were sold in multiple transactions at prices ranging from $30.03 - $31.0299. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 15:27 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 100 | $2.59 | $259.00 |
DisclosureSEC source: 0001193125-26-175965 · ownership.xml · nonDerivative · entry 3 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 15:27 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,001 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001193125-26-175965 · ownership.xml · derivative · entry 5 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,307 Underlying: Common Stock · 7,001 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F4 · derivative.exercise_date: 25% of the option vested on February 3, 2020 with the remaining shares vesting in 1/48 monthly installments thereafter. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 15:27 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 7,001 | $30.05 | $210,401.75 |
DisclosureSEC source: 0001193125-26-175965 · ownership.xml · nonDerivative · entry 2 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,083 F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F2 · price: These shares were sold in multiple transactions at prices ranging from $30 - $30.15. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 15:27 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 7,001 | $2.59 | $18,132.59 |
DisclosureSEC source: 0001193125-26-175965 · ownership.xml · nonDerivative · entry 1 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 21:38 UTC | Pharvaris N.V. PHVS · Entity 4374 | Tax withholdingCommon Stock | 226 | $28.78 | $6,504.28 |
DisclosureSEC source: 0001193125-26-164355 · ownership.xml · nonDerivative · entry 1 Lu Peng · CIK 0001972159 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,083 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units on April 11, 2026 and April 12, 2026. The shares were withheld on April 16, 2026 at a fair market value of $28.78 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.